An international task force has updated recommendations for axial and peripheral spondyloarthritis, and psoriatic arthritis, which include treat-to-target recommendations…
Search results for: musculoskeletal disease
Prospects for Treating Patients with Arthritis in African Countries with Few Rheumatologists
At present, the U.S. has approximately 5,000 full-time adult rheumatologists. By the year 2025, that number will decline to roughly 3,600.1 Sounds dire, right? Hold that thought. Question: What country has 99 million people and no adult rheumatologists? Answer: Ethiopia.2 The Nigerian Story And then there is Africa’s most populous country, Nigeria, with roughly 170…
On the Road in Rajasthan: Vehicular-Caused Bone, Joint Damage in India
In the good old days, physicians routinely made house calls. The decision to visit the literal bedside of a patient was practical: hospital services were primitive and often offered too little benefit to justify an emergency journey by the patient. These physicians carried leather bags, sometimes called Gladstones, that were filled with instruments for eventualities…
ACR, EULAR Approve New Classification Criteria for Primary Sjögren’s Syndrome
Classification criteria for primary Sjögren’s syndrome (SS) have been approved by the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR), validating an international set of classification criteria for SS using standards set by both organizations. Those criteria can now be found in the 2016 ACR/EULAR Classification Criteria for Primary Sjögren’s Syndrome: A…
Potential Benefits, Pitfalls of Biosimilars Reviewed at EULAR 2016
LONDON—The availability of a biosimilar form of infliximab has dramatically increased the number of Norwegians taking one form or another of the drug, an expert on biosimilars said in a debate-style session at the Annual Congress of the European League Against Rheumatism (EULAR 2016). The expanded uptake of Remicade (infliximab) and its biosimilar, Remsima (international…
New Criteria Released for Macrophage Activation Syndrome in Juvenile Idiopathic Arthritis
Although most systemic juvenile idiopathic arthritis patients don’t develop macrophage activation syndrome (MAS), the approximately 10% who do have this serious complication can experience widespread, massive inflammation, debilitating symptoms and even death. To improve understanding of MAS among physicians and advance efforts to develop effective therapies to treat it, a panel of 28 international pediatric…
ARHP Past Presidents Share Ties to Tucson, Arizona
The American College of Rheumatology (ACR) recognized the 50th anniversary of the Association of Rheumatology Health Professionals (ARHP) during the ACR/ARHP Annual Meeting this past November in San Francisco. The University of Arizona Arthritis Center followed up with a reception in Tucson to honor past presidents of the ARHP. The Tucson area has the highest…
University of Alabama at Birmingham’s Division of Clinical Immunology & Rheumatology Recognized for Excellence
An interdisciplinary and collaborative environment is a critical factor for the advancement of basic science and clinical research in the academic environment, says William J. Koopman, MD, former director of the University of Alabama at Birmingham’s (UAB’s) Division of Clinical Immunology and Rheumatology. And in 1977, when he was being recruited by Division Director J….
Opinion: Adhering to Standards of Care Helps Manage Risk
Medicare and other third-party payers have started predicating reimbursement on adherence to standards of care. Post hoc chart reviews have resulted in substantial take-backs for failure to adhere to those values in cardiology, pulmonology and expanding to other areas. Outpatient medicine is also being subjected to such scrutiny. The question of standards and who sets…
Hospital for Special Surgery Focuses on Measuring, Adding Value
Value is the ratio of quality to cost. The delivery and measurement of healthcare quality, however, is complex. “We first need to understand and define the health outcomes that are important to patients. Then we need to put into place care pathways that will lead to those outcomes, and finally we need mechanisms to measure…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 94
- Next Page »